RTI Surgical Holdings, Inc.® Provides Business Updates
DEERFIELD, Ill., June 30, 2020 (GLOBE NEWSWIRE) — RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today […]
Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.
STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and […]
New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company […]
Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
GAITHERSBURG, Md., June 30, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced dosing of […]
MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
YAVNE, Israel, June 30, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to […]
Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns
CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License […]
Marinus Pharmaceuticals Provides Pipeline Update
Status Epilepticus pivotal Phase 3 trial on-track to begin in Q3 2020CDKL5 Deficiency Disorder Phase 3 trial results in Q3 […]
XP Inc. Acquires Stake in Fintech Antecipa Entering the Receivables Financing Market
SÃO PAULO, Brazil, June 30, 2020 (GLOBE NEWSWIRE) — XP Inc. (Nasdaq: XP), a leading, technology-driven financial services platform and […]
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy
– Potential accelerated pathway to NDA submission – – Clinical program of five Phase 3 trials provides multiple options for NDA […]
Osmotica Pharmaceuticals US LLC Submits Amended NDA for Arbaclofen Extended Release Tablets to U.S. Food and Drug Administration
— Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis —— Demonstrated efficacy, tolerability […]
